X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Europe

Expansion of Antitumor Natural Killer Cells Using Anti-CD16 Antibody and Irradiated Autologous Peripheral Blood Mononuclear Cells

Yuvraj_pawp by Yuvraj_pawp
20th November 2017
in Europe, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Natural killer (NK) cells are lymphocytes of the innate immune system and are important in controlling tumors and infections without depending on the recognition of specific antigens. The activation of NK cells occur via NK cell receptor interactions, including the CD 16 (Fc-gamma) receptors that bind antibodies (eg. IgG) attached to pathogens and infected cells. The CD16 receptor is involved in antibody-dependent cellular cytotoxicity, a process associated with the effectiveness of antibody-based cancer immunotherapies.

CD16 can induce NK cell activation without additional receptor signals; therefore, it can be used as a strategy to promote NK cell expansion. Various cytokines have been used to expand NK cells but without adequate effectiveness. Cancer cells lines have been used as feeder cells (used to nourish cultured tissue cells) for the large-scale expansion of NK cells. However, this requires methods to limit the growth of the feeder cells so that these do not contaminate the expanded NK cells.

To circumvent this issue, researchers instead used irradiated autologous peripheral blood mononuclear cells for large-scale expansion of purified cytotoxic NK cells activated with anti-CD16 monoclonal antibody. They exposed peripheral blood mononuclear cells to a radiation dose sufficient to inactivate T cells during NK expansion. The irradiated donor cells were then cultured with anti-CD16 antibody. This combination induced a stronger increase in expanded NK cells compared to irradiated cells alone. Further, flow cytometry analysis showed that the anti-CD16 and irradiated cell combination upregulated NK cell-activating receptors.

NK cells expanded via the combination method were found to secrete the cytokine INF-gamma after stimulation with target cancer cells (human cancer cell lines). Further, coculturing of target cancer cells with expanded NK cells led to increased target cell death. Tumor growth was suppressed in immunodeficient mice inoculated with lung and colon cancer cells after injection with NK cells expanded by the combination method. The results of these experiments demonstrate that NK cell expansion using anti-CD16 antibody and irradiated peripheral blood mononuclear cells can provide sufficient expansion of purified cytotoxic human NK cells with strong in vitro and in vivo antitumor activity and applicability to antitumor immunotherapy.

Lee, H., Son, C., Koh, E., Bae, J., Kang, C., Yang, K., & Park, Y. (2017). Expansion of cytotoxic natural killer cells using irradiated autologous peripheral blood mononuclear cells and anti-CD16 antibody. Scientific Reports, 7(1). doi:10.1038/s41598-017-09259-1

Previous Post

Sobi begins phase 3 study evaluating safety and efficacy of anakinra to treat Still’s disease

Next Post

Sumitomo Dainippon Pharma and Angelini Announce Partnership for Commercialization of Latuda in Europe

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post

Sumitomo Dainippon Pharma and Angelini Announce Partnership for Commercialization of Latuda in Europe

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In